Trial NCT04262388

View at ClinicalTrials.gov 
Org. Study IDs: DOME
Secondary IDs: 19-6280

Last trial update was posted on 2020-11-17

MeSH Interventions

Durvalumab

MeSH Conditions

Adenocarcinoma Carcinoma Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell Lung Neoplasms Squamous Cell Carcinoma of Head and Neck

Other Conditions

Non-small Cell Lung Cancer Pancreatic Ductal Adenocarcinoma

Stopping Reasons

Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does not support further evaluation of this doublet.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID